Keywords
biologicals
sanitary surveillance
agreement
Swiss Webster
B6D2F1
How to Cite
Abstract
The recombinant human erythropoietin (rhEPO) is a glycoprotein hormone. In face of the broad range of rhEPO-containing products in the market, the scope of their therapeutic indication and the characteristics of the rhEPO users, the biological activity testing is of high relevance for their batches releasing process. The potency testing is a laboratory evaluation for assessing the effectiveness of the final product, recommended by the European Pharmacopoeia (Ph. Eur.). This paper aimed at evaluating the agreement between the biological activity results obtained when the strain of mice-B6D2F1, recommended by Ph. Eur., was used in comparison to the Swiss Webster (SW). Twenty-two batches were assayed using these two mice strains, and a total of 44 valid assays were obtained with satisfactory results. In none of these analyses, neither repeating assays nor results combination were needed. The inter-strains variation and the accuracy were evaluated, and the following results were detected: Coefficient of Variation (VC) < 10 % and Relative Error % (RE) < 10 %, respectively. The tested lineage provided homogeneous results, and no statistically significant difference between them was found. The SW strain might be used as an alternative in place of B6D2F1 for performing the biological potency evaluation of rhEPO.
References
1. Jacobson. LO, Goldwasser L, Fried W, Plzak L. Role of the kidney in erythropoiesis. Nature. 1957; 170:633–4. [DOI:10.1038/179633a0].
2. Fried W. The liver as a source of extrarenal erythropoietin production. Blood. 1972;40: 671-7.
3. Zanjani ED, Ascensão JL, Mcglave PB, Banisadre M, Ash RC. Studies on the liver to kidney switch of erythropoietin production. J Clin Invest.1981;67:1183-8. [DOI: 10.1172/JCI110133].
4. Koury ST, Bondurant MC, Semenza GL, Koury MJ. The use of in situ hybridization to study erythropoietin gene expression in murine kidney and liver. Microsc Res Tech. 1993;25(1):29–39. [DOI: 10.1002/jemt.1070250106].
5. Fisher JW, Koury S, Ducey T, Mendel S. Erythropoietin production by interstitial cells of hypoxic monkey kidneys. Br J Haematol. 1996;95(1):27-32. [DOI: 10.1046/j.1365-2141.1996.d01-1864.x].
6. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem. 1977;252: 5558-64.
7. Lin F, Suggs S, Lin C, Browne JK, Smalling R, Egrie JC, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA. 1985;82(22):7580-4. [DOI: 10.1073/pnas.82.22.7580].
8. Faris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having major orthopedic operation. The American Erythropoietin Study Group. J Bone Joint Surg Am.1996;78(1):62-72.
9. Rizzo JD, Seidenfeld9. J, Piper M, Aronson N, Lichtin A, Littlewood TJ. Erythropoietin: a paradigm for the development of practice guidelines. Hematology Am Soc Hematol Educ Program.2001;10-30. [DOI: 10.1182/asheducation-2001].
10. Saag MS, Bowers P, Leitz GJ, Levine AM. Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients. AIDS Res Hum Retroviruses. 2004;20(10):1037-45. [DOI:10.1089/aid.2004.20.1037].
11. Aapro MS, Dale DC, Blasi M, Sarokhan B, Ahmed F, Woodman RC. Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy. Support Care Cancer. 2006;14(12):1184-94. [DOI: 10.1007/s00520-006-0076-z]
12. Guan X, Chen L. Role of erythropoietin in cancer-related anaemia: a double-edged sword?J Int Med Res. 2008;36(1):1-8. [DOI: 10.1177/147323000803600101].
13. World health Organization - WHO. WHO Drug Information. Geneva, Switzerland. 2010;24(1):40p.
14. Brinks V, Hawe A, Basmeleh AHH, Joachin-Rodriguez L, Somsen GW, Jiskoot W, et al. Quality Original and Biosimilar Epoetin Products. Pharm. Res. 2011;28(2):386-93. [DOI: 10.1007/s11095-010-0288-2].
15. Council of Europe. Erythropoietin concentrated solution, Monograph 1316. Strasbourg, France. Pharmeuropa. 2011.[DOI: 180.168.103.34:7947/zl/EP7/1316E].
16. European Centre for the Validation of Alternative Methods - ECVAM. Statement on the batch potency testing of erythropoietin concentrated solution. Altern Lab Anim. 2002;30:487-9.
17. Albertengo ME, Valcarce GA, Oliva LM, Baiges DL, Alonso BS, Chiale CA. Eritropoyetina recombinante humana:método de valoración in vivo con ratones normocitémicos. Sangre (Barc).1999;44:357-63.
18. Ramos AS, Schmidt CA, Andrade SS, Fronza M, Rafferty B, Dalmora SL. Biological evaluation of recombinant human erythopoietin in pharmaceutical products. Braz J Med Biol Res. 2003;36(11):1561-9. [DOI: 10.1590/S0100-879X2003001100014].
19. Schmidt CA, Ramos AS, da Silva JEP, Fronza M, Dalmora SL. Avaliação da atividade e caracterização de Eritropoietina humana recombinante em produtos farmacêuticos. Arq Bras Endocrinol Metab. 2003;47:183-9. [DOI: 10.1590/S0004-27302003000200012].
20. Barth T, Oliveira PR, D’Avila FB, Dalmora SL. Validation of the normocythemic mice bioassay for the potency evaluation of recombinant human erythropoietin in pharmaceutical formulations. J AOAC Int.2008;91(2):285-91. [DOI: 10.1590/S1516-8913201500228].
21. Silva IB, Mattos KA, Dick PC, Almeida AS, Silva RG, Hokama DA, Paumgartten FJR. Ensaio de potência da alfaepoetina: Comparação de camundongos Swiss Webster, NIH, C57BL6, BALB/c com o híbrido B6D2F1. Vig Sanit Debate. 2013;1:49-58
22. Taconic. Animals models list. B6D2F1. 2011. [acesso 2011 ago 22] Disponível em: [http://www.taconic.com/wmspage.cfm?parm1=763].
23. Universidade Federal Fluminense. 2011. Classificação Genética dos Animais de Laboratório. [acesso 2011 ago 22]. Disponível em: [www.uff.br/animaislab/ap6.doc].
24. Mouse Genome Informatics – MGI. International Committee on Standardized Genetic Nomenclature for Mice. Guidelines for nomenclature of mouse and rat strains. Revised: September 2010. [acesso 2011 mai 25]. Disponível em: [www.informatics.jax.org/mgihome/nomen/strains.shtml#definition]. [DOI: 10.1177/0300985810374837].
25. Taconic. Animals models list. 2013. [acesso 2013 mar 10]. Disponível em: [http://www.taconic.com/wmspage.cfm?parm1=856].
26. Instituto Nacional de Controle da Qualidade em Saúde - INCQS. POP 65.3430.042: ensaio para avaliação “in vivo” da potência biológica de eritropoetina humana recombinante. Rev.01. Rio de Janeiro. 2012. 17p. (Manual da Qualidade. Seção 4.3).
27. European Directorate for the Quality of Medicines & HealthCare - EDQM. CombiStats, version 5.0, 2013.
28. Council of Europe. Statistical analysis. Strasbourg, France. Pharmeuropa. 2012.
29. Bland JM, Altman DG. Statistical method for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-10. [DOI: 10.1590/S1678-77572011000500009].
30. Food and Drug Administration - FDA. Guidance for industry: bioanalytical method validation. Rockville, 2001.
31. Hoffman D, kringle R. A total error approach for the validation of quantitative analytical methods. Pharm Res. 2007;24(6):1157-63.
32. United States Phamacopoeia – U S P. Mon. <1033>; Biological Assay Validation, in: USP 35 NF30, 1stSup. Rockville, 2012.
33. International Organization for Standardization - ISO. ISO N° 3534-2. Statistics -Vocabulary and Symbols. Applied Statistics. Part 2. Geneva, Switzerland, 2006.
34. Lopes MC. Avaliação da potência biológica da eritropoietina humana recombinante em produtos farmacêuticos: estudo comparativo entre as linhagens de camundongos B6D2F1 e Swiss Webster[dissertação de mestrado]. Rio de Janeiro (RJ): Instituto Nacional de Controle de Qualidade em Saúde, Fundação Oswaldo Cruz; 2004. [DOI: 10.1590/S0004-27302003000200012].
35. Costa RN, Abreu CLC, Nascimento MC, Nogueira ACMA, Delgado IF. Evaluation of the applicability of swiss webster lineage on the biological potency test of recombinant human erythropoietin. Int J Biosaf Biosec. 2010;1:49-59.
36. World Health Organization – WHO. Validation. In: WHO, A WHO guide to good manufacturing practice (GMP) requirements. Geneva, Switzerland, 1997.
37. Fitzgerald EA, Gallagher M, Hunter WS, Seligmann EB Jr.Use of the antibody assay in immunized mice for the determination of rabies vaccine potency. Dev Biol Stand. 1978;40:183-6.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2016 Instituto Adolfo Lutz Journal
Downloads
